EasySep™ Human Naïve CD4+ T Cell Isolation Kit II

Immunomagnetic negative isolation of untouched human naïve CD4+ T cells

EasySep™ Human Naïve CD4+ T Cell Isolation Kit II

Immunomagnetic negative isolation of untouched human naïve CD4+ T cells

From: 960 USD
Catalog #
(Select a product)
Immunomagnetic negative isolation of untouched human naïve CD4+ T cells
Add to Wish List

Product Advantages


  • Fast, easy-to-use and column-free

  • Up to 98% purity

  • Untouched, viable cells

What's Included

  • EasySep™ Human Naïve CD4+ T Cell Isolation Kit II (Catalog #17555)
    • EasySep™ Human Naïve CD4+ T Cell Isolation Cocktail II, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
  • RoboSep™ Human Naïve CD4+ T Cell Isolation Kit II (Catalog #17555RF)
    • EasySep™ Human Naïve CD4+ T Cell Isolation Cocktail II, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Easily and efficiently isolate highly purified human naïve CD4+ T cells (CD3+CD4+CD45RA+CD45RO-) from fresh or previously frozen human peripheral blood mononuclear cell (PBMC) samples by immunomagnetic negative selection, with the EasySep™ Human Naïve CD4+ T Cell Isolation Kit II. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep™ negative selection procedure, unwanted cells are labeled with antibody complexes and magnetic particles. Unwanted cells expressing the following markers are targeted for removal: CD8, CD14, CD16, CD19, CD20, CD25, CD36, CD45RO, CD56, CD61, CD66b, CD123, GlyA, TCRgd, and HLA-DR. The magnetically labeled cells are then separated from the untouched desired naïve CD4+ T cells by using an EasySep™ magnet and simply pouring or pipetting the desired cells into a new tube. Following magnetic cell isolation in as little as 11 minutes, the desired naïve CD4+ T cells are ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction.

This kit replaces the EasySep™ Human Naïve CD4+ T Cell Enrichment Kit (Catalog #19155) and EasySep™ Human Naïve CD4+ T Cell Isolation Kit (Catalog #19555) for even faster cell isolations.

Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Alternatively, choose ready-to-use, ethically sourced, primary Human Peripheral Blood CD4+CD45RA+ T Cells, Frozen isolated with EasySep™ Human Naïve CD4+ T Cell Isolation Kit II. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
19555
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• Easy 50 EasySep™ Magnet (Catalog #18002)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
Subtype
Cell Isolation Kits
Cell Type
T Cells, T Cells, CD4+
Species
Human
Sample Source
PBMC
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Immunology

Data Figures

Figure 1. Typical EasySep™ Human Naive CD4 T Cell Isolation Profile

Starting with fresh mononuclear cells, the naïve CD4+ T cell content (CD3+CD4+CD45RA+CD45RO-) of the isolated fraction is typically 96.6 ± 1.5% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and final isolated fractions are 13.0% and 97.3%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17555RF
Lot #
All
Language
English
Catalog #
17555
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17555RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17555RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17555RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17555
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17555
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Publications (13)

LINC01871 is exclusively expressed in T and NK cells and is highly induced upon CD4+ T cell activation U. Kalim et al. iScience 2025 Oct

Abstract

SummaryLong intergenic noncoding RNAs (lincRNAs) regulate biological processes in health and disease. Recent findings highlight the importance of lincRNAs in regulating T cell development and function. Here, we identified a lincRNA, LINC01871, which is highly induced upon CD4+ T cell activation and is predominantly located in the cytoplasm. The anti-inflammatory cytokine TGF-β was found to suppress its expression. Silencing LINC01871 led to a modest decrease in IL-2 secretion. Notably, LINC01871 expression was highly specific to NK cells and T cells in several cross-tissue single cell RNA-seq atlases. These data suggest that LINC01871 is specifically expressed in T and NK cells and may contribute to T cell-mediated immunity in humans. Graphical abstract Highlights•LINC01871 is a cytoplasmic lincRNA induced upon CD4+ T cell activation•TGF-β negatively regulates LINC01871 expression•Expression of LINC01871 is restricted to effector and memory T and NK cells Immunology; Molecular biology; Cell biology
Single-cell ultra-high-throughput multiplexed chromatin and RNA profiling reveals gene regulatory dynamics Nature Methods 2025 May

Abstract

Enhancers and transcription factors (TFs) are crucial in regulating cellular processes. Current multiomic technologies to study these elements in gene regulatory mechanisms lack multiplexing capability and scalability. Here we present single-cell ultra-high-throughput multiplexed sequencing (SUM-seq) for co-assaying chromatin accessibility and gene expression in single nuclei. SUM-seq enables profiling hundreds of samples at the million cell scale and outperforms current high-throughput single-cell methods. We demonstrate the capability of SUM-seq to (1) resolve temporal gene regulation of macrophage M1 and M2 polarization to bridge TF regulatory networks and immune disease genetic variants, (2) define the regulatory landscape of primary T helper cell subsets and (3) dissect the effect of perturbing lineage TFs via arrayed CRISPR screens in spontaneously differentiating human induced pluripotent stem cells. SUM-seq offers a cost-effective, scalable solution for ultra-high-throughput single-cell multiomic sequencing, accelerating the unraveling of complex gene regulatory networks in cell differentiation, responses to perturbations and disease studies. This work presents SUM-seq, an ultra-high-throughput method for co-profiling chromatin accessibility and gene expression in single nuclei across multiplexed samples, advancing the study of gene regulation in diverse biological systems.
TIGIT deficiency promotes autoreactive CD4+ T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis Y. Lai et al. Nature Communications 2025 May

Abstract

Polymyositis (PM) is a systemic autoimmune disease characterized by muscular inflammatory infiltrates and degeneration. T-cell immunoreceptor with Ig and ITIM domains (TIGIT) contributes to immune tolerance by inhibiting T cell-mediated autoimmunity. Here, we show that a reduced expression of TIGIT in CD4+ T cells from patients with PM promotes these cells’ differentiation into Th1 and Th17 cells, which could be rescued by TIGIT overexpression. Knockout of TIGIT enhances muscle inflammation in a mouse model of experimental autoimmune myositis. Mechanistically, we find that TIGIT deficiency enhances CD28-mediated PI3K/AKT/mTOR co-stimulatory pathway, which promotes glucose oxidation, citrate production, and increased cytosolic acetyl-CoA levels, ultimately inducing epigenetic reprogramming via histone acetylation. Importantly, pharmacological inhibition of histone acetylation suppresses the differentiation of Th1 and Th17 cells, alleviating muscle inflammation. Thus, our findings reveal a mechanism by which TIGIT directly affects the differentiation of Th1 and Th17 T cells through metabolic‒epigenetic reprogramming, with important implications for treating systemic autoimmune diseases. Aberrant activation of autoreactive T cells is a hallmark of autoimmune diseases. Here, by analysing CD4 T cells from patients with polymyositis and mice with experimental autoimmune myositis, the authors show that TIGIT limits the differentiation of inflammatory Th1 and Th17 cells via a metabolic-epigenetic mechanism, which involves the inhibition of CD28-mediated PI3K/AKT/mTOR costimulatory signaling.